Charles River Laboratories International (CRL) and Valo Health said Tuesday they identified their first advanceable product candidate for lupus and other autoimmune diseases using Logica.
The companies said Logica, an AI-powered drug development program born from their strategic partnership, translates biological insights into optimized preclinical assets.
The Logica Advanceable Lead program combines Valo's DNA-encoded libraries and Opal Computational Platform with Charles River's high-throughput screening to produce advanceable leads, they said.
CRL shares were 0.8% higher in recent premarket activity.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。